Previous 10 | Next 10 |
CHARLESTOWN, Mass. , April 13, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the 22 nd Annual Ne...
2023-03-23 08:44:04 ET Solid Biosciences press release ( NASDAQ: SLDB ): Q4 Net loss of $15.2M Solid had $213.7 million in cash, cash equivalents, and available-for-sale securities as of December 31, 2022, compared to $207.8 million as of December 31, 2021. This financia...
- Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases; Closed concurrent $75 million private placement - - Company remains on track to submit IND for SGT 003, a next-generation gene therapy for patien...
CHARLESTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will participate in the BMO Biopharma Sp...
CHARLESTOWN, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the Barclays Global Heal...
CHARLESTOWN, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the SVB Securities Global...
- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy intended for treatment of patients with Duchenne muscular dystrophy - - White paper submitte...
Solid Biosciences ( NASDAQ: SLDB ) and Phlox Therapeutics entered a strategic collaboration to develop precision medicines for genetic cardiac diseases. The research collaboration will target a severe form of genetic dilated cardiomyopathy (DCM). The strategic collaboration wi...
Research collaboration to target severe form of genetic dilated cardiomyopathy Collaboration strengthens Solid Biosciences’ scientific capabilities and commercial potential in cardiac therapy Collaboration allows Phlox Therapeutics to leverage Solid Biosciences’ ve...
– Investigational New Drug (IND) application for SGT-003, next-generation gene therapy for Duchenne muscular dystrophy utilizing novel capsid AAV-SLB101, expected in 2H-2023 – – Candidate selection and transition manufacturing process to transient tra...
News, Short Squeeze, Breakout and More Instantly...
Solid Biosciences Inc. Company Name:
SLDB Stock Symbol:
NASDAQ Market:
Solid Biosciences Inc. Website:
2024-07-06 13:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,847 restricted stock units (“...
CHARLESTOWN, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the Company has been added to the broad-market Russell 3000 ® Index as ...